ARCA biopharma, Inc. (NASDAQ:ABIO) Files An 8-K Financial Statements and Exhibits
Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

ARCA biopharma, Inc. Exhibit
EX-99.1 2 abio-ex991_7.htm EX-99.1 abio-ex991_7.htm   Exhibit 99.1         GENETIC-AF phase 2b clinical trial results presented in late breaking presentation at european society of cardiology heart failure 2018 world congress —————————————————————————————————— End-of-Phase 2 Meeting with the U.S. FDA Scheduled for the Last Week of June to Review Gencaro Phase 2 Data and Future Development Plan   Westminster,…
To view the full exhibit click here

About ARCA biopharma, Inc. (NASDAQ:ABIO)

ARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company’s lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.